GenoScreen’s Post

[#news] 📢 Exciting news for leprosy treatment. De Jong’s team at Institute of Tropical Medicine Antwerp (Antwerp, Belgium) has recently published promising Phase 2 trial results in PLOS Medicine, highlighting the safety of a preventive treatment combining bedaquiline and rifampicin for leprosy. In line with this progress, we at GenoScreen (Lille, France) have integrated the atpE gene - a key resistance marker for bedaquiline in M. leprae - into our diagnostic assay, Deeplex® Myc-Lep. This enhancement boosts our test’s ability to assess potential resistance to this novel preventive treatment, helping to reach the goals of the World Health Organization roadmap “Towards zero leprosy by 2030”. 📄 Read the study here: https://lnkd.in/envPEHzm With the updated Deeplex Myc-Lep, GenoScreen continues to lead in the fight against leprosy. ➡️ Learn more about Deeplex Myc-Lep: https://lnkd.in/etF_H3TB #Leprosy #Diagnostics #Genomics #GenoScreen #DeeplexMycLep #WHO2030 #deeplex Have questions or want to learn more about our solutions? We're here to support your research and projects! 📧 Email: commercial.dept@genoscreen.fr 📞 Phone: +33(0) 362 263 777 🌐 Visit our website: https://lnkd.in/eXesRaKY

To view or add a comment, sign in

Explore topics